Project Grant R01CA293027
Award Date 4/15/26
Completion Date 3/31/31
Dollars Obligated $781K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University's Health Sciences Division a $683,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This award supports research on tumor-penetrating stromal modification of pancreatic ductal adenocarcinoma (PDAC) through investigation of the αvβ5 integrin pathway. The project focuses on developing and evaluating the IRGD tumor-penetrating peptide as...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a Project Grant of $159,304 under the Cancer Research Manpower program (CFDA 93.398) for the period July 1, 2025 through June 30, 2027. This award supports research training and investigator development focused on identifying signaling pathways that govern tumoricidal macrophage function in pancreatic cancer. The project aims to elucidate receptor-ligand interactions that enable...
- Federal Grant Award Summary The National Cancer Institute awarded a $168,000 Project Grant to Albert Einstein College of Medicine under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2028. The grant supports research to elucidate the mechanisms of pancreatic ductal adenocarcinoma (PDAC) dormancy and minimal residual disease (MRD), with particular focus on identifying and validating therapeutic targets. The research will investigate the role...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $275,990 under the Cancer Research Manpower program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. on September 2, 2025, with a completion date of August 31, 2026. This award supports the development of engineered living materials (ELMs) as programmable therapeutic implants for pancreatic cancer treatment. The research addresses the critical challenge of poor drug delivery in pancreatic ductal...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under its Cancer Treatment Research program (CFDA 93.395), awarded Cold Spring Harbor Laboratory a $778,873 Project Grant on June 23, 2025, with a completion date of May 31, 2030. This award funds research to identify and validate SOAT1 (Sterol-O-Acyl Transferase 1) as a therapeutic target in pancreatic ductal adenocarcinoma (PDAC). The research will utilize genetically engineered mouse models and inducible degron systems...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $119,858 to the Regents of the University of Minnesota under the Cancer Biology Research program (CFDA 93.396) on August 7, 2025, for a project extending through July 31, 2030. This project grant supports fundamental research aimed at elucidating and overcoming T cell dysfunction in pancreatic ductal adenocarcinoma (PDA), a disease notoriously resistant to immunotherapy. The research program comprises three...
- Federal Grant Award Summary The National Cancer Institute awarded $148,626 to the Sloan-Kettering Institute for Cancer Research on September 28, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research training and career development in cancer biology. This Project Grant, which extends through March 27, 2028, funds an interdisciplinary research initiative investigating Interferon E (IFNE) as a tumor suppressor and potential therapeutic target in pancreatic ductal...
- Federal Grant Award Summary Purdue University received a $457,503 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective August 28, 2025, with completion targeted for July 31, 2030. The award funds fundamental research investigating posttranslational regulation of macropinocytosis in pancreatic ductal adenocarcinoma (PDAC), specifically examining the role of Protein Phosphatase 2A (PP2A) and its B56A subunit in modulating...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a $682,673 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026, with completion targeted for April 30, 2031. This five-year award supports research into the adaptation and evolution of resistance to pan-RAS inhibition in pancreatic ductal adenocarcinoma (PDAC), a disease that claims over 52,000 lives annually in the United...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill $384,630 under the Cancer Biology Research program (CFDA 93.396) on April 10, 2026, for a project titled "Identifying Immune-Mediated Mechanisms of RAS Inhibitor Efficacy and Resistance in Pancreatic Cancer." The award, with a completion date of March 31, 2027, funds research designed to elucidate how tumor-immune microenvironment remodeling contributes to the...